| HOME >> BIOLOGY >> TECHNOLOGY |
ATLANTA, Oct. 4 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has appointed David P. Lang as vice president of market development for CryoLife International Inc. In this newly created position, Mr. Lang will have responsibility for coordinating and developing the international marketing and distribution strategies for PerClot, a novel hemostatic agent that the Company recently licensed from Starch Medical Inc. Mr. Lang will report to Gerald B. Seery, senior vice president sales and marketing and president, CryoLife International, Inc.
A graduate of Harvard University with a degree in economics, Mr. Lang began his career at Medtronic in 1970 and has held sales and marketing positions of increasing responsibility throughout his medical device marketing and management career. From 2008 to 2010, Mr. Lang served as the president and was a consultant to Starch Medical Inc. He served as vice president of international sales and marketing for Medafor, Inc. from 2001 to 2008, where he established their European, Latin American and Asian distribution networks.
"We are pleased to welcome David, an experienced international sales and marketing executive, to CryoLife's international management team. David brings a wealth of experience in the medical device industry to the Company, and has a proven track record of success in developing international markets and distribution networks for hemostatic agents. He is certain to make a significant contribution to our success in rolling out PerClot," said Steven G. Anderson, president and chief executive officer. "The expansion of our international product portfolio to include the PerClot technology platform and its complementary delivery devices and the addition of David to our int
'/>"/>
| SOURCE CryoLife, Inc. Copyright©2010 PR Newswire. All rights reserved |